Comparative Pharmacology
Head-to-head clinical analysis: DILOR 400 versus SOMOPHYLLIN CRT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILOR 400 versus SOMOPHYLLIN CRT.
DILOR-400 vs SOMOPHYLLIN-CRT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phosphodiesterase inhibitor; inhibits PDE4 and PDE5, leading to increased intracellular cAMP and cGMP, resulting in bronchodilation and vasodilation.
Theophylline acts as a bronchodilator via nonselective phosphodiesterase inhibition, increasing intracellular cAMP levels. It also antagonizes adenosine receptors and may have anti-inflammatory effects.
400 mg orally every 6 to 8 hours; maximum daily dose 2400 mg.
Theophylline 400 mg orally once daily (24-hour extended-release). Titrate based on serum theophylline levels; target trough 5-15 mcg/mL.
None Documented
None Documented
3.1 hours (terminal elimination half-life; may increase in hepatic impairment or congestive heart failure)
Terminal elimination half-life: 8-10 hours in adults (non-smokers); prolonged to 12-16 hours in elderly or hepatic impairment; reduced to 4-6 hours in smokers (CYP1A2 induction).
Renal (70% unchanged), hepatic metabolism (30%)
Primarily hepatic metabolism (90%) via CYP1A2 and CYP3A4; renal excretion of unchanged drug accounts for ~10% in adults, with minor biliary/fecal elimination (<1%).
Category C
Category C
Bronchodilator
Bronchodilator